|Description||Resistance Gene Testing|
|VENTURE FUNDING TOTAL||$49.6M|
|Series A, 12/09 |
Life Sciences Partners
|Series A, 5/10 ||€1.5M|
|Series A, 5/11 ||€4.5M|
|Series A, 10/11 |
Forbion Capital Partners
Roche Venture Fund
Curetis AG focuses on multiparameter testing of many analytes in a single run, providing broad panels of combined pathogen and resistance gene detection for a wide range of diseases.
Curetis integrates todayÂ´s molecular diagnostics laboratory into one instrument for the detection of severe bacterial infections as a first target application. However, the universal platform will also allow the future expansion into other clinical applications with additional market opportunities beyond infectious diseases.